NasdaqCM:PLSEMedical Equipment
New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE)
Pulse Biosciences, Inc. recently appointed experienced healthcare technology executive Maria Sainz to its Board of Directors and announced that late-breaking first-in-human feasibility data for its nPulse Cardiac Catheter Ablation System will be presented at the 31st Annual AF Symposium 2026 in February.
This combination of seasoned leadership and the public sharing of early clinical outcomes for a core cardiac ablation technology could meaningfully influence how clinicians and investors...